Phase II study of CC-4047 in patients with metastatic hormone-refractory prostate cancer (HRPCa)

Sison, B.; Bond, T.; Amato, Robert J.; Crawford, D.; Crighton, Frances

doi:10.1200/jco.2004.22.90140.4701

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this trial was underpowered, with only 75 patients, its results suggest an incremental benefit in disease progression and stabilization. Other novel thalidomide analogues with immunomodulatory and potentially antiangiogenic activity but without significant neurotoxicity, such as Revlimid (Celgene, Warren, NJ) and Actimid (Celgene), are moving into phase II trials after initial studies demonstrated their activity and safety [42,43]. DN101 represents a new formulation of calcitriol, a vitamin D analogue that has demonstrated preclinical synergy with docetaxel and improved PSA responses and median survival in phase II trials when used in combination with docetaxel [44].…”

Section: Combinations Of Chemotherapy and Biologic Agentsmentioning

confidence: 99%

Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies

Armstrong

Carducci

2005

Curr Oncol Rep

View full text Add to dashboard Cite

Our understanding of the role of chemotherapy for advanced prostate cancer has improved considerably in 2004 with the publication of two large randomized phase III trials and the approval by the US Food and Drug Administration of docetaxel and prednisone for metastatic hormone-refractory disease. Although treatment is still considered palliative in nature, studies of chemotherapy for metastatic hormone-refractory prostate cancer (HRPC) have demonstrated improved overall survival compared with older regimens as well as clinically significant improvements in important endpoints, such as quality of life and time to progression. In particular, docetaxel has emerged as first-line therapy on an every-3-week schedule for metastatic HRPC, replacing mitoxantrone, as recently reported in the TAX327 trial. Docetaxel and estramustine combinations have the disadvantage of significant cardiovascular and gastrointestinal toxicity, and further use of estramustine is likely unwarranted as first-line therapy. Future trials examining novel biologic agents and combination therapies should use single-agent docetaxel as the reference standard. The role of chemotherapy for advanced disease in the neoadjuvant or adjuvant setting, in biochemically (PSA) relapsed patients, and as second-line therapy for relapsed disease, remains a subject of active clinical investigation.

show abstract

Section: Combinations Of Chemotherapy and Biologic Agentsmentioning

confidence: 99%